Home Merck Statement on FDA Advisory Committee for GRASTEK (Timothy Grass Pollen Allergen Extract), Mercks Investigational Sublingual Allergy Immunotherapy Tablet
 

Keywords :   


Merck Statement on FDA Advisory Committee for GRASTEK (Timothy Grass Pollen Allergen Extract), Mercks Investigational Sublingual Allergy Immunotherapy Tablet

2013-12-13 01:17:00| Merck.com - Product News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued the following statement after the conclusion of the Allergenic Products Advisory Committee of the U.S. Food and Drug Administration (FDA) meeting to discuss GRASTEK (Timothy grass pollen allergen extract). Language: English Contact: MerckMedia:Pamela Eisele, 908-423-5042orRobert Consalvo, 908-423-6595orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: statement committee advisory grass

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
24.115 2 PG
24.11215103TW 17svtw
24.11 Switch light
24.11Dr.SLUMP 19
24.11layover LP
24.11PING i230 6W 5
24.11BTS CD
24.11HG 56
More »